Bl. Hartmann et al., Bcl-2 interferes with the execution phase, but not upstream events, in glucocorticoid-induced leukemia apoptosis, ONCOGENE, 18(3), 1999, pp. 713-719
Due to their growth arrest- and apoptosis-inducing ability, glucocorticoids
(GC) are widely used in the therapy of various lymphoid malignancies. Cell
death is associated with activation of members of the interleukin-1 beta-c
onverting enzyme (ICE) protease/caspase family and, is presumably prevented
by the anti-apoptotic protein Bcl-2. To further address the role of Bcl-2
in CC-mediated cytotoxicity, we generated subclones of the GC-sensitive hum
an T-cell acute lymphoblastic leukemia line CCRF-CEM, in which transgenic B
cl-2 expression is regulated by tetracycline. Up to about 48 h, exogenous B
cl-2 almost completely protected these cells from apoptosis, digestion of p
oly-ADP ribose polymerase (PARP) and generation of Asp-Glu-Val-Asp cleaving
(DEVDase) activity. However, when the cells were cultured for another 24 h
in the continuous presence of GC, they underwent massive apoptosis that wa
s associated with DEVDase activity and PARP cleavage. Bcl-2 did not markedl
y affect GC-mediated growth arrest, thereby separating the anti-proliferati
ve from the apoptosis-inducing effect of GC. Moreover, Bcl-2 did not preven
t the dramatic reduction in the levels of several mRNAs observed during GC
treatment, including the transgenic Bcl-2 mRNA. Thus, Bcl-2 can be placed u
pstream of effector caspase activation, but downstream of other GC-regulate
d events, such as growth arrest and the potentially critical repression of
steady state levels of multiple mRNA.